Drug Landscape ›
Bupropion-Naltrexone ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 27
Most-reported reactions
Generalised Tonic-Clonic Seizure — 6 reports (22.22%) Drug Interaction — 5 reports (18.52%) Abnormal Weight Gain — 3 reports (11.11%) Bundle Branch Block Right — 3 reports (11.11%) Metabolic Disorder — 3 reports (11.11%) Weight Increased — 3 reports (11.11%) Condition Aggravated — 1 report (3.7%) Dizziness — 1 report (3.7%) Dyskinesia — 1 report (3.7%) Dysmenorrhoea — 1 report (3.7%)
Source database →
Bupropion-Naltrexone in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Bupropion-Naltrexone approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Bupropion-Naltrexone in United States?
WW International Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.